Vistagen Therapeutics (VTGN) Amortizatization of Intangibles (2013 - 2015)
Vistagen Therapeutics (VTGN) posted Amortizatization of Intangibles of $14000.0 for Q3 2015, down 97.46% sequentially from $550800.0 in Q2 2015, and down 95.58% YoY from $317100.0 in Q3 2014.
Vistagen Therapeutics (VTGN) Amortizatization of Intangibles (2013 - 2015) Analysis & Trends
Vistagen Therapeutics has reported Amortizatization of Intangibles for 3 years, with the latest figure at $14000.0 in Q3 2015.
- Quarterly Amortizatization of Intangibles fell 95.58% year-over-year to $14000.0 in Q3 2015, while the trailing twelve-month figure through Jun 2016 was $564800.0 (down 83.59% YoY) and the FY2015 annual result came in at $3.4 million, up 426.88% from the prior year.
- Amortizatization of Intangibles eased to $14000.0 in Q3 2015 per VTGN's latest filing, from $550800.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $2.1 million in Q1 2015 and troughed at -$97400.0 in Q1 2013.
- A 3-year average of $407218.2 and a median of $283900.0 in 2014 frame the typical range for Amortizatization of Intangibles.
- The widest YoY moves for Amortizatization of Intangibles: up 631.7% in 2015, down 95.58% in 2015.
- Over 3 years, Amortizatization of Intangibles stood at $154100.0 in 2013, then surged by 221.67% to $495700.0 in 2014, then sank by 97.18% to $14000.0 in 2015.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $14000.0, $550800.0, and $2.1 million for Q3 2015, Q2 2015, and Q1 2015 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Vistagen Therapeutics | 10.49 Mn | 10.49 Mn | - | 145,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 14,000.00 |
| Sep 30, 2015 | 14,000.00 |
| Jun 30, 2015 | 550,800.00 |
| Jun 30, 2015 | 550,800.00 |
| Mar 31, 2015 | 2.08 Mn |
| Mar 31, 2015 | 2.08 Mn |
| Dec 31, 2014 | 495,700.00 |
| Dec 31, 2014 | 495,700.00 |
| Sep 30, 2014 | 317,100.00 |
| Sep 30, 2014 | 317,100.00 |
| Jun 30, 2014 | 481,900.00 |
| Jun 30, 2014 | 481,900.00 |
| Mar 31, 2014 | 283,900.00 |
| Mar 31, 2014 | 283,900.00 |
| Dec 31, 2013 | 154,100.00 |
| Dec 31, 2013 | 154,100.00 |
| Sep 30, 2013 | 108,000.00 |
| Sep 30, 2013 | 108,000.00 |
| Jun 30, 2013 | 94,000.00 |
| Jun 30, 2013 | 94,000.00 |